Celgene Corporation (CELG)

[bcpark]

I dont think that the street realizes this and as a shareholder I just wanted to share some insight. Hang tight!

Genzyme Preannounced Solid Unaudited Q4 and FY 2008 Results. On 1/13/09 Genzyme announced Q4 and full year 2008 unaudited revenue and Q4 EPS results which were largely in line with consensus estimates. Namely $1.17B, $4.6B, and non-GAAP EPS of $1.01-1.04/diluted share vs.estimates of $1.2B, $4.63B, and $1.01.

Within 2009 the shares should trade in-line with the market until the Synvisc-One approval decision passes. Following this event, shares should modestly appreciate as we approach the EMeA approval of the Myozyme 4,000L bioreactors in Belgium which should occur between April and June. Upon approval I expect shares to uncoil as approval should immediately and significantly impact the bottom line

1.) pent up patient demand to accelerate market share, 2.) built up inventory would allow Genzyme to meet demand and lower initial COGS and 3.) the elimination of MTAP will decrease R&D cost.